| Title |
Expression of the SART1 tumor rejection antigen in renal cell carcinoma
|
|---|---|
| Published in |
Urolithiasis, June 2000
|
| DOI | 10.1007/s002400000103 |
| Pubmed ID | |
| Authors |
I. Shintaku, N. Kawagoe, S. Yutani, S. Hoshi, S. Orikasa, O. Yoshizumi, K. Itoh |
| Abstract |
We have previously described the SART1 gene, which encodes both the SART1(259) antigen expressed in the cytosol of the majority of squamous cell carcinomas and some adenocarcinomas and the SART1(800) antigen expressed in the nucleus of the majority of proliferating cells. The SART1(259) antigen is recognized by HLA-A24 and A26-restricted cytotoxic T lymphocytes (CTLs). The present study investigated the expression of these two antigens in renal cell carcinomas (RCCs) in order to identify an appropriate molecule for use in specific immunotherapy for RCC patients. These two antigens were detected in all RCC cell lines and cells of the primary cultures of the RCCs tested. Further, they were detectable in cells of the primary cultures of non-tumorous kidney tissues. In contrast to these cultured cells, SART1(259) was detectable in only a few uncultured RCC tissues (5/20, 25%) and was undetectable in non-tumorous kidney tissues. SART1(800) was also scarcely detectable in uncultured RCC tissues (3/20, 15%) and non-tumorous kidney tissues (4/20, 20%). HLA-A2402-restricted and tumor-specific CTL (KE4-CTL) used for the cloning of the SART1 gene showed significant levels of cytotoxicity to both the cells from the RCC cell line and the cells from the primary cultures of RCC tissues, but did not lyse any normal cells, including cells from the primary cultures of non-tumorous kidney tissues. The SART1-derived peptide at positions 690-698 induced HLA-A24 restricted CTLs cytotoxic to RCC cells from peripheral blood mononuclear cells (PBMCs) of RCC patients. Therefore, the SART1 peptide could be an appropriate molecule for use in peptide-based specific immunotherapy for RCC patients. |
Mendeley readers
The data shown below were compiled from readership statistics for 9 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 9 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 3 | 33% |
| Other | 2 | 22% |
| Student > Master | 2 | 22% |
| Student > Ph. D. Student | 1 | 11% |
| Professor > Associate Professor | 1 | 11% |
| Other | 0 | 0% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 3 | 33% |
| Biochemistry, Genetics and Molecular Biology | 2 | 22% |
| Agricultural and Biological Sciences | 1 | 11% |
| Nursing and Health Professions | 1 | 11% |
| Immunology and Microbiology | 1 | 11% |
| Other | 1 | 11% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 July 2018.
All research outputs
#8,535,472
of 25,374,917 outputs
Outputs from Urolithiasis
#230
of 716 outputs
Outputs of similar age
#13,330
of 39,990 outputs
Outputs of similar age from Urolithiasis
#1
of 2 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 716 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one is in the 36th percentile – i.e., 36% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 39,990 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them